Neos Therapeutics (NASDAQ: NEOS) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neos Therapeutics and Neuralstem, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neos Therapeutics 0 0 5 0 3.00
Neuralstem 0 0 2 0 3.00

Neos Therapeutics currently has a consensus price target of $16.20, suggesting a potential upside of 116.00%. Neuralstem has a consensus price target of $2.19, suggesting a potential upside of 63.43%. Given Neos Therapeutics’ higher probable upside, equities research analysts clearly believe Neos Therapeutics is more favorable than Neuralstem.

Insider and Institutional Ownership

44.3% of Neos Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Neuralstem shares are owned by institutional investors. 5.2% of Neos Therapeutics shares are owned by insiders. Comparatively, 19.3% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


This table compares Neos Therapeutics and Neuralstem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neos Therapeutics -511.74% -611.78% -80.97%
Neuralstem -198,573.91% -321.78% -127.53%

Risk and Volatility

Neos Therapeutics has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500.

Earnings & Valuation

This table compares Neos Therapeutics and Neuralstem’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Neos Therapeutics $15.62 million 13.48 -$69.70 million ($4.45) -1.69
Neuralstem $16,246.00 999.43 -$18.67 million N/A N/A

Neuralstem has higher revenue, but lower earnings than Neos Therapeutics.


Neos Therapeutics beats Neuralstem on 6 of the 11 factors compared between the two stocks.

About Neos Therapeutics

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

About Neuralstem

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with's FREE daily email newsletter.